Health news
The Food and Drug Administration (FDA) has approved Rinvoq® (upadacitinib) for the treatment of adults with active ankylosing spondylitis (AS) who have had an inadequate response or intolerance to 1 or more tumor necrosis factor…
Interim results were announced from a phase 3 study evaluating bimekizumab, an investigational interleukin (IL)-17A and IL-17F inhibitor, in adults with active ankylosing spondylitis. The ongoing multicenter, randomized, double-blind, placebo-controlled BE MOBILE 2 study (ClinicalTrials.gov…
The Food and Drug Administration (FDA) has approved the supplemental New Drug Application for Xeljanz®/Xeljanz® XR (tofacitinib) for the treatment of adults with active ankylosing spondylitis (AS) who have had an inadequate response or intolerance…
The Food and Drug Administration has approved Cyltezo® (adalimumab-adbm) as the first interchangeable biosimilar to Humira® (adalimumab). Cyltezo, a tumor necrosis factor (TNF) blocker, is indicated to treat adults with rheumatoid arthritis, psoriatic arthritis, ankylosing…
Among patients with axial spondyloarthritis (axSpA), an increase in traditional cardiovascular (CV) risk factors is correlated with an increase in disease activity, according to study results published in Therapeutic Advances in Musculoskeletal Disease. Occurrence of…
© 2005-2021 Top-Meds - All rights reserved. Our website services, content, and products are for informational purposes only. Top-Meds does not provide medical advice, diagnosis, or treatment. | Medical News 2021